You are being asked to take part in this study because you have non-small cell lung cancer and your cancer has a change (mutation) in a agene responsible for producing a protein called BRAF. This mutation can cause uncontrolled growth in your tumor. The purpose of this study is to learn about the effects of the study drugs, sasanlimab, encorafenib, and binimetinib, when given as a combination treatment for your type of lung cancer.